Big day at the EAU Annual Meeting n London today, as our colleague Dr James Buteau (Nuclear Medicine Physician, Peter MacCallum Cancer Centre, Melbourne), reads out the PRIMARY 2 RCT at the Practice-Changing Plenary in London. Plus a simultaneous publication in Lancet Oncology. Big news for the early detection of prostate cancer, especially for patients with normal or equivocal MRI scans. 

Declan Murphy and Renu Eapen are joined by James and senior author, Prof Louise Emmett (St Vincent's Hospital, Sydney), to discuss the journey from our first PSMA PET/CT scans in 2014, to the proPSMA trial, the PRIMARY trial, and now the PRIMARY 2 RCT. We discuss why this should now mean that patients with a PIRADS 2 or 3 prostate MRI, and a persisting suspicion such as high PSA density, should be considered for a PSMA PET/CT, rather than a systematic biopsy. 

Huge congratulations to all the investigators across Australia for seeing this trial through to successful completion, and to all the patients who participated. 

Acknowledgements:

Sponsored by Peter MacCallum Cancer Centre, with financial support from the Prostate Cancer Foundation (PCF), St Vincent’s Curran Foundation, ProsTIC, Peter Mac Foundation, NHMRC and ANZUP

Links:
PRIMARY 2 trial in Lancet Oncology